A 0 1 0 1 O
suspicious 2 12 2 12 O
central 13 20 13 20 O
gland 21 26 21 26 O
lesion 27 33 27 33 O
on 34 36 34 36 O
MP 37 39 37 39 B-treatment
- 39 40 39 40 I-treatment
MRI 40 43 40 43 I-treatment
must 44 48 44 48 O
have 49 53 49 53 O
a 54 55 54 55 O
distinct 56 64 56 64 O
lesion 65 71 65 71 O
on 72 74 72 74 O
the 75 78 75 78 O
apparent 79 87 79 87 B-clinical_variable
diffusion 88 97 88 97 I-clinical_variable
coefficient 98 109 98 109 I-clinical_variable
( 110 111 110 111 I-clinical_variable
ADC 111 114 111 114 I-clinical_variable
) 114 115 114 115 I-clinical_variable

Age 0 3 116 119 B-age
≥ 4 5 120 121 O
35 6 8 122 124 B-lower_bound
and 9 12 125 128 O
≤ 13 14 129 130 O
85 15 17 131 133 B-upper_bound
years 18 23 134 139 I-upper_bound
at 24 26 140 142 O
signing 27 34 143 150 O
of 35 37 151 153 O
consent 38 45 154 161 O

An 0 2 162 164 O
anti 3 7 165 169 B-treatment
- 7 8 169 170 I-treatment
androgen 8 16 170 178 I-treatment
( 17 18 179 180 O
e.g. 18 22 180 184 O
, 22 23 184 185 O
bicalutamide 24 36 186 198 B-treatment
at 37 39 199 201 O
50 40 42 202 204 B-upper_bound
mg 43 45 205 207 I-upper_bound
per 46 49 208 211 I-upper_bound
day 50 53 212 215 I-upper_bound
po 54 56 216 218 O
) 56 57 218 219 O
is 58 60 220 222 O
recommended 61 72 223 234 O
to 73 75 235 237 O
start 76 81 238 243 O
prior 82 87 244 249 O
to 88 90 250 252 O
LHRH 91 95 253 257 B-treatment
agonist 96 103 258 265 I-treatment
injection 104 113 266 275 I-treatment
( 114 115 276 277 O
not 115 118 277 280 O
recommended 119 130 281 292 O
for 131 134 293 296 O
LHRH 135 139 297 301 B-treatment
antagonist 140 150 302 312 I-treatment
injection 151 160 313 322 I-treatment
) 160 161 322 323 O
and 162 165 324 327 O
is 166 168 328 330 O
recommended 169 180 331 342 O
to 181 183 343 345 O
not 184 187 346 349 O
be 188 190 350 352 O
administered 191 203 353 365 O

Androgen 0 8 366 374 B-treatment
deprivation 9 20 375 386 I-treatment
therapy 21 28 387 394 I-treatment
( 29 30 395 396 I-treatment
ADT 30 33 396 399 I-treatment
) 33 34 399 400 I-treatment
is 35 37 401 403 O
at 38 40 404 406 O
the 41 44 407 410 O
discretion 45 55 411 421 O
of 56 58 422 424 O
the 59 62 425 428 O
treating 63 71 429 437 O
physician 72 81 438 447 O

Biopsy 0 6 448 454 B-treatment
confirmed 7 16 455 464 O
adenocarcinoma 17 31 465 479 B-cancer
( 32 33 480 481 O
including 33 42 481 490 O
ductal 43 49 491 497 O
) 49 50 497 498 O
of 51 53 499 501 O
the 54 57 502 505 O
prostate 58 66 506 514 O

Distinct 0 8 515 523 O
lesion 9 15 524 530 O
on 16 18 531 533 O
dynamic 19 26 534 541 B-treatment
contrast 27 35 542 550 I-treatment
- 35 36 550 551 I-treatment
enhanced 36 44 551 559 I-treatment
MRI 45 48 560 563 I-treatment
( 49 50 564 565 I-treatment
DCE 50 53 565 568 I-treatment
- 53 54 568 569 I-treatment
MRI 54 57 569 572 I-treatment
) 57 58 572 573 I-treatment
with 59 63 574 578 O
early 64 69 579 584 O
enhancement 70 81 585 596 O
and 82 85 597 600 O
later 86 91 601 606 O
washout 92 99 607 614 O

Gleason 0 7 615 622 B-clinical_variable
8 8 9 623 624 B-lower_bound
- 9 10 624 625 O
10 10 12 625 627 B-upper_bound
or 13 15 628 630 O
a 16 17 631 632 O
PSA 18 21 633 636 B-clinical_variable
of 22 24 637 639 O
> 25 26 640 641 O
15 26 28 641 643 B-lower_bound
ng 29 31 644 646 I-lower_bound
/ 31 32 646 647 I-lower_bound
ml 32 34 647 649 I-lower_bound

Gleason 0 7 650 657 B-clinical_variable
score 8 13 658 663 I-clinical_variable
6 14 15 664 665 B-lower_bound
- 15 16 665 666 O
10 16 18 666 668 B-upper_bound

It 0 2 669 671 O
may 3 6 672 675 O
be 7 9 676 678 O
initiated 10 19 679 688 O
no 20 22 689 691 O
more 23 27 692 696 O
than 28 32 697 701 O
3 33 34 702 703 B-upper_bound
months 35 41 704 710 I-upper_bound
prior 42 47 711 716 I-upper_bound
to 48 50 717 719 O
the 51 54 720 723 O
signing 55 62 724 731 O
of 63 65 732 734 O
consent 66 73 735 742 O

It 0 2 743 745 O
must 3 7 746 750 O
be 8 10 751 753 O
started 11 18 754 761 O
prior 19 24 762 767 O
to 25 27 768 770 O
the 28 31 771 774 O
start 32 37 775 780 O
of 38 40 781 783 O
radiotherapy 41 53 784 796 B-treatment

Karnofsky 0 9 797 806 B-clinical_variable
or 10 12 807 809 O
Eastern 13 20 810 817 B-clinical_variable
Cooperative 21 32 818 829 I-clinical_variable
Oncology 33 41 830 838 I-clinical_variable
Group 42 47 839 844 I-clinical_variable
( 48 49 845 846 I-clinical_variable
ECOG 49 53 846 850 I-clinical_variable
) 53 54 850 851 I-clinical_variable
performance 55 66 852 863 I-clinical_variable
status 67 73 864 870 I-clinical_variable
may 74 77 871 874 O
be 78 80 875 877 O
used 81 85 878 882 O
to 86 88 883 885 O
estimate 89 97 886 894 O
Zubrod 98 104 895 901 B-clinical_variable

No 0 2 902 904 O
concurrent 3 13 905 915 O
, 13 14 915 916 O
active 15 21 917 923 O
malignancy 22 32 924 934 B-cancer
, 32 33 934 935 O
other 34 39 936 941 O
than 40 44 942 946 O
nonmetastatic 45 58 947 960 B-cancer
skin 59 63 961 965 I-cancer
cancer 64 70 966 972 I-cancer
or 71 73 973 975 O
early 74 79 976 981 O
stage 80 85 982 987 O
chronic 86 93 988 995 B-cancer
lymphocytic 94 105 996 1007 I-cancer
leukemia 106 114 1008 1016 I-cancer
( 115 116 1017 1018 O
well 116 120 1018 1022 O
- 120 121 1022 1023 O
differentiated 121 135 1023 1037 O
small 136 141 1038 1043 B-cancer
cell 142 146 1044 1048 I-cancer
lymphocytic 147 158 1049 1060 I-cancer
lymphoma 159 167 1061 1069 I-cancer
) 167 168 1069 1070 O

No 0 2 1071 1073 O
evidence 3 11 1074 1082 O
of 12 14 1083 1085 O
metastasis 15 25 1086 1096 B-cancer
by 26 28 1097 1099 O
any 29 32 1100 1103 O
clinical 33 41 1104 1112 O
criteria 42 50 1113 1121 O
or 51 53 1122 1124 O
available 54 63 1125 1134 O
radiographic 64 76 1135 1147 B-treatment
tests 77 82 1148 1153 I-treatment
( 83 84 1154 1155 O
N0M0 84 88 1155 1159 O
by 89 91 1160 1162 O
clinical 92 100 1163 1171 O
or 101 103 1172 1174 O
imaging 104 111 1175 1182 O
criteria 112 120 1183 1191 O
) 120 121 1191 1192 O

No 0 2 1193 1195 O
previous 3 11 1196 1204 O
history 12 19 1205 1212 O
of 20 22 1213 1215 O
radical 23 30 1216 1223 B-treatment
/ 30 31 1223 1224 I-treatment
total 31 36 1224 1229 I-treatment
prostatectomy 37 50 1230 1243 I-treatment
( 51 52 1244 1245 O
suprapubic 52 62 1245 1255 B-treatment
prostatectomy 63 76 1256 1269 I-treatment
is 77 79 1270 1272 O
acceptable 80 90 1273 1283 O
) 90 91 1283 1284 O

No 0 2 1285 1287 O
previous 3 11 1288 1296 O
pelvic 12 18 1297 1303 B-treatment
radiotherapy 19 31 1304 1316 I-treatment

Prostate 0 8 1317 1325 B-clinical_variable
- 8 9 1325 1326 I-clinical_variable
specific 9 17 1326 1334 I-clinical_variable
Antigen 18 25 1335 1342 I-clinical_variable
( 26 27 1343 1344 I-clinical_variable
PSA 27 30 1344 1347 I-clinical_variable
) 30 31 1347 1348 I-clinical_variable
≤ 32 33 1349 1350 O
100 34 37 1351 1354 B-upper_bound
ng 38 40 1355 1357 I-upper_bound
/ 40 41 1357 1358 I-upper_bound
mL 41 43 1358 1360 I-upper_bound
within 44 50 1361 1367 O
( 51 52 1368 1369 O
+ 52 53 1369 1370 O
/- 53 55 1370 1372 O
) 55 56 1372 1373 O
4 57 58 1374 1375 B-upper_bound
months 59 65 1376 1382 I-upper_bound
of 66 68 1383 1385 O
signing 69 76 1386 1393 O
of 77 79 1394 1396 O
consent 80 87 1397 1404 O

Subjects 0 8 1405 1413 O
with 9 13 1414 1418 O
T3 14 16 1419 1421 B-chronic_disease
disease 17 24 1422 1429 I-chronic_disease
based 25 30 1430 1435 O
on 31 33 1436 1438 O
digital 34 41 1439 1446 O
rectal 42 48 1447 1453 O
exam 49 53 1454 1458 O
( 54 55 1459 1460 O
DRE 55 58 1460 1463 O
) 58 59 1463 1464 O

Suspicious 0 10 1465 1475 O
peripheral 11 21 1476 1486 O
zone 22 26 1487 1491 O
or 27 29 1492 1494 O
central 30 37 1495 1502 O
gland 38 43 1503 1508 O
lesion 44 50 1509 1515 O
on 51 53 1516 1518 O
MP 54 56 1519 1521 B-treatment
- 56 57 1521 1522 I-treatment
MRI 57 60 1522 1525 I-treatment

T1 0 2 1526 1528 B-lower_bound
- 2 3 1528 1529 O
T3 3 5 1529 1531 B-upper_bound
disease 6 13 1532 1539 O
based 14 19 1540 1545 O
on 20 22 1546 1548 O
digital 23 30 1549 1556 O
rectal 31 37 1557 1563 O
exam 38 42 1564 1568 O

The 0 3 1569 1572 O
total 4 9 1573 1578 O
length 10 16 1579 1585 O
planned 17 24 1586 1593 O
must 25 29 1594 1598 O
be 30 32 1599 1601 O
≤ 33 34 1602 1603 O
30 35 37 1604 1606 B-upper_bound
months 38 44 1607 1613 I-upper_bound

Zubrod 0 6 1614 1620 B-clinical_variable
performance 7 18 1621 1632 I-clinical_variable
status 19 25 1633 1639 I-clinical_variable
≤ 26 27 1640 1641 O
2 28 29 1642 1643 B-upper_bound

distinct 0 8 1644 1652 O
lesion 9 15 1653 1659 O
on 16 18 1660 1662 O
the 19 22 1663 1666 O
ADC 23 26 1667 1670 B-clinical_variable
map 27 30 1671 1674 O
( 31 32 1675 1676 O
Value 32 37 1676 1681 B-clinical_variable
< 38 39 1682 1683 O
1000 39 43 1683 1687 B-upper_bound
) 43 44 1687 1688 O

map 0 3 1689 1692 O
( 4 5 1693 1694 O
Value 5 10 1694 1699 O
< 11 12 1700 1701 O
1000 12 16 1701 1705 B-upper_bound
) 16 17 1705 1706 O

must 0 4 1707 1711 O
be 5 7 1712 1714 O
decided 8 15 1715 1722 O
( 16 17 1723 1724 O
none 17 21 1724 1728 O
, 21 22 1728 1729 O
short 23 28 1730 1735 O
- 28 29 1735 1736 O
term 29 33 1736 1740 O
or 34 36 1741 1743 O
long 37 41 1744 1748 O
- 41 42 1748 1749 O
term 42 46 1749 1753 O
as 47 49 1754 1756 O
counted 50 57 1757 1764 O
from 58 62 1765 1769 O
the 63 66 1770 1773 O
luteinizing 67 78 1774 1785 B-treatment
hormone 79 86 1786 1793 I-treatment
- 86 87 1793 1794 I-treatment
releasing 87 96 1794 1803 I-treatment
hormone 97 104 1804 1811 I-treatment
( 105 106 1812 1813 I-treatment
LHRH 106 110 1813 1817 I-treatment
) 110 111 1817 1818 I-treatment
agonist 112 119 1819 1826 I-treatment
or 120 122 1827 1829 O
antagonist 123 133 1830 1840 B-treatment
injection 134 143 1841 1850 I-treatment
) 143 144 1850 1851 O
prior 145 150 1852 1857 O
to 151 153 1858 1860 O
enrollment 154 164 1861 1871 O

should 0 6 1872 1878 O
have 7 11 1879 1883 O
a 12 13 1884 1885 O
bone 14 18 1886 1890 B-treatment
scan 19 23 1891 1895 I-treatment
within 24 30 1896 1902 O
( 31 32 1903 1904 O
+ 32 33 1904 1905 O
/- 33 35 1905 1907 O
) 35 36 1907 1908 O
4 37 38 1909 1910 B-upper_bound
months 39 45 1911 1917 I-upper_bound
of 46 48 1918 1920 O
signing 49 56 1921 1928 O
of 57 59 1929 1931 O
consent 60 67 1932 1939 O
that 68 72 1940 1944 O
is 73 75 1945 1947 O
without 76 83 1948 1955 O
evidence 84 92 1956 1964 O
of 93 95 1965 1967 O
metastasis 96 106 1968 1978 B-cancer

